Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance
Introduction: Epidemiological studies have suggested an increased vascular risk in patients with multiple sclerosis (MS). There is increasing evidence of the beneficial effects of GLP-1 agonists (GLP-1a) in preventing vascular complications and slowing the progression of neurodegeneration. Our objec...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/13/11162 |
| _version_ | 1797591505558306816 |
|---|---|
| author | Miroslava Hardonova Pavel Siarnik Monika Sivakova Bianka Sucha Adela Penesova Zofia Radikova Andrea Havranova Richard Imrich Miroslav Vlcek Ingrid Zitnanova Georgi Krastev Maria Kiacikova Branislav Kollar Peter Turcani |
| author_facet | Miroslava Hardonova Pavel Siarnik Monika Sivakova Bianka Sucha Adela Penesova Zofia Radikova Andrea Havranova Richard Imrich Miroslav Vlcek Ingrid Zitnanova Georgi Krastev Maria Kiacikova Branislav Kollar Peter Turcani |
| author_sort | Miroslava Hardonova |
| collection | DOAJ |
| description | Introduction: Epidemiological studies have suggested an increased vascular risk in patients with multiple sclerosis (MS). There is increasing evidence of the beneficial effects of GLP-1 agonists (GLP-1a) in preventing vascular complications and slowing the progression of neurodegeneration. Our objective was to explore the changes in the endothelial function of MS patients after 12 months of GLP-1a therapy. We also explored the role of lipoprotein subfractions and the antioxidant capacity of plasma. Methods: MS patients were enrolled in a prospective, unicentric study. GLP-1a (dulaglutide) was administered to 13 patients. The control population consisted of 12 subjects. Endothelial function was determined by peripheral arterial tonometry and expressed as reperfusion hyperemia index (RHI). Trolox equivalent antioxidant capacity (TEAC) was used to assess the total antioxidant capacity of the plasma. The levels of lipoprotein subfractions were evaluated. Results: The GLP-1a group did not have a significant change in their RHIs after 12 months (2.1 ± 0.6 vs. 2.1 ± 0.7; <i>p</i> = 0.807). However, a significant increase in their TEACs was observed (4.1 ± 1.4 vs. 5.2 ± 0.5 mmol/L, <i>p</i> = 0.010). On the contrary, the subjects in the control group had a significant worsening of their RHIs (2.1 ± 0.5 vs. 1.8 ± 0.6; <i>p</i> = 0.030), without significant changes in their TEACs. Except for a significant decrease in very-low-density lipoprotein (VLDL) (30.8 ± 10.2 vs. 22.6 ± 8.3 mg/dL, <i>p</i> = 0.043), no other significant changes in the variables were observed in the control group. VLDL levels (beta = −0.637, <i>p</i> = 0.001), the use of GLP-1a therapy (beta = 0.560, <i>p</i> = 0.003), and small LDL (beta = 0.339, <i>p</i> = 0.043) were the only significant variables in the model that predicted the follow-up RHI. Conclusion: Our results suggest that the application of additional GLP-1a therapy may have atheroprotective and antioxidant effects in MS patients with high MS activity and thus may prospectively mitigate their vascular risk. However, the lipoprotein profile may also play an important role in the atherogenic risk of MS subjects. |
| first_indexed | 2024-03-11T01:38:25Z |
| format | Article |
| id | doaj.art-be6c860459c34afa8c5fd6e3ef667f1e |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T01:38:25Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-be6c860459c34afa8c5fd6e3ef667f1e2023-11-18T16:49:00ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-07-0124131116210.3390/ijms241311162Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox BalanceMiroslava Hardonova0Pavel Siarnik1Monika Sivakova2Bianka Sucha3Adela Penesova4Zofia Radikova5Andrea Havranova6Richard Imrich7Miroslav Vlcek8Ingrid Zitnanova9Georgi Krastev10Maria Kiacikova11Branislav Kollar12Peter Turcani131st Department of Neurology, Faculty of Medicine, Comenius University, 813 69 Bratislava, Slovakia1st Department of Neurology, Faculty of Medicine, Comenius University, 813 69 Bratislava, Slovakia1st Department of Neurology, Faculty of Medicine, Comenius University, 813 69 Bratislava, Slovakia1st Department of Neurology, Faculty of Medicine, Comenius University, 813 69 Bratislava, SlovakiaInstitute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, SlovakiaInstitute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, SlovakiaInstitute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, SlovakiaInstitute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, SlovakiaInstitute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, SlovakiaInstitute of Medical Chemistry, Biochemistry and Clinical Biochemistry, Faculty of Medicine, Comenius University, 811 08 Bratislava, SlovakiaDepartment of Neurology, Faculty Hospital, 917 75 Trnava, SlovakiaDepartment of Neurology, Faculty Hospital, 911 01 Trencin, Slovakia1st Department of Neurology, Faculty of Medicine, Comenius University, 813 69 Bratislava, Slovakia1st Department of Neurology, Faculty of Medicine, Comenius University, 813 69 Bratislava, SlovakiaIntroduction: Epidemiological studies have suggested an increased vascular risk in patients with multiple sclerosis (MS). There is increasing evidence of the beneficial effects of GLP-1 agonists (GLP-1a) in preventing vascular complications and slowing the progression of neurodegeneration. Our objective was to explore the changes in the endothelial function of MS patients after 12 months of GLP-1a therapy. We also explored the role of lipoprotein subfractions and the antioxidant capacity of plasma. Methods: MS patients were enrolled in a prospective, unicentric study. GLP-1a (dulaglutide) was administered to 13 patients. The control population consisted of 12 subjects. Endothelial function was determined by peripheral arterial tonometry and expressed as reperfusion hyperemia index (RHI). Trolox equivalent antioxidant capacity (TEAC) was used to assess the total antioxidant capacity of the plasma. The levels of lipoprotein subfractions were evaluated. Results: The GLP-1a group did not have a significant change in their RHIs after 12 months (2.1 ± 0.6 vs. 2.1 ± 0.7; <i>p</i> = 0.807). However, a significant increase in their TEACs was observed (4.1 ± 1.4 vs. 5.2 ± 0.5 mmol/L, <i>p</i> = 0.010). On the contrary, the subjects in the control group had a significant worsening of their RHIs (2.1 ± 0.5 vs. 1.8 ± 0.6; <i>p</i> = 0.030), without significant changes in their TEACs. Except for a significant decrease in very-low-density lipoprotein (VLDL) (30.8 ± 10.2 vs. 22.6 ± 8.3 mg/dL, <i>p</i> = 0.043), no other significant changes in the variables were observed in the control group. VLDL levels (beta = −0.637, <i>p</i> = 0.001), the use of GLP-1a therapy (beta = 0.560, <i>p</i> = 0.003), and small LDL (beta = 0.339, <i>p</i> = 0.043) were the only significant variables in the model that predicted the follow-up RHI. Conclusion: Our results suggest that the application of additional GLP-1a therapy may have atheroprotective and antioxidant effects in MS patients with high MS activity and thus may prospectively mitigate their vascular risk. However, the lipoprotein profile may also play an important role in the atherogenic risk of MS subjects.https://www.mdpi.com/1422-0067/24/13/11162multiple sclerosisGLP-1 agonistslipoprotein subfractionsredox balanceendothelial dysfunction |
| spellingShingle | Miroslava Hardonova Pavel Siarnik Monika Sivakova Bianka Sucha Adela Penesova Zofia Radikova Andrea Havranova Richard Imrich Miroslav Vlcek Ingrid Zitnanova Georgi Krastev Maria Kiacikova Branislav Kollar Peter Turcani Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance International Journal of Molecular Sciences multiple sclerosis GLP-1 agonists lipoprotein subfractions redox balance endothelial dysfunction |
| title | Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance |
| title_full | Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance |
| title_fullStr | Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance |
| title_full_unstemmed | Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance |
| title_short | Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance |
| title_sort | endothelial function in patients with multiple sclerosis the role of glp 1 agonists lipoprotein subfractions and redox balance |
| topic | multiple sclerosis GLP-1 agonists lipoprotein subfractions redox balance endothelial dysfunction |
| url | https://www.mdpi.com/1422-0067/24/13/11162 |
| work_keys_str_mv | AT miroslavahardonova endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance AT pavelsiarnik endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance AT monikasivakova endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance AT biankasucha endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance AT adelapenesova endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance AT zofiaradikova endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance AT andreahavranova endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance AT richardimrich endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance AT miroslavvlcek endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance AT ingridzitnanova endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance AT georgikrastev endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance AT mariakiacikova endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance AT branislavkollar endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance AT peterturcani endothelialfunctioninpatientswithmultiplesclerosistheroleofglp1agonistslipoproteinsubfractionsandredoxbalance |